What is the recommended antibiotic for Beta-Hemolytic Streptococci (BHS) infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Penicillin is the first-line antibiotic for beta-hemolytic streptococci infections, with oral penicillin V 500 mg twice daily for 10 days being the recommended treatment for adults with streptococcal pharyngitis. This recommendation is based on the most recent and highest quality study available, which confirms that penicillin is effective in treating group A streptococcal pharyngitis and preventing complications such as rheumatic fever 1. The study also notes that beta-hemolytic streptococci, particularly Group A (Streptococcus pyogenes), remain universally susceptible to penicillin, which works by inhibiting bacterial cell wall synthesis.

Some key points to consider when treating beta-hemolytic streptococci infections include:

  • The importance of complete treatment to prevent complications like rheumatic fever or post-streptococcal glomerulonephritis
  • The use of alternative antibiotics, such as macrolides like azithromycin or clindamycin, for patients with penicillin allergy
  • The consideration of testing household members who may be asymptomatic carriers in cases of recurrent infections
  • The fact that antimicrobial resistance has not been a significant issue in the treatment of group A streptococcal pharyngitis in the United States, with no clinical isolate of group A Streptococcus anywhere in the world documented to be resistant to penicillin 1

It's also worth noting that the American Heart Association recommends penicillin as the treatment of choice for group A streptococcal pharyngitis, due to its cost-effectiveness, narrow spectrum of activity, and long-standing proven efficacy 1. Overall, the evidence suggests that penicillin is the most effective and recommended antibiotic for treating beta-hemolytic streptococci infections.

From the FDA Drug Label

In three double-blind controlled studies, conducted in the United States, azithromycin (12 mg/kg once a day for 5 days) was compared to penicillin V (250 mg three times a day for 10 days) in the treatment of pharyngitis due to documented Group A β-hemolytic streptococci (GABHS or S. pyogenes)

Approximately 1% of azithromycin-susceptible S pyogenes isolates were resistant to azithromycin following therapy.

In cases of β-hemolytic streptococcal infections, treatment should continue for at least 10 days.

The recommended antibiotic for Beta-Hemolytic Streptococci (BHS) infection is penicillin V or azithromycin.

  • Azithromycin is given at a dose of 12 mg/kg once a day for 5 days.
  • Penicillin V is given at a dose of 250 mg three times a day for 10 days. Treatment should continue for at least 10 days 2, 3.

From the Research

Recommended Antibiotics for Beta-Hemolytic Streptococci (BHS) Infection

  • Penicillin is currently recommended by the American Academy of Pediatrics and American Heart Association as first-line therapy for GABHS infections 4
  • Erythromycin is recommended for those allergic to penicillin 4
  • Cephalosporins or azithromycin are preferred following penicillin treatment failures in selected patients as first-line therapy, based on a history of penicillin failures or lack of compliance and for impetigo 4
  • Clindamycin administration may improve outcomes in patients with serious streptococcal infections, and its use in combination with benzylpenicillin has been shown to be of benefit 5, 6
  • The use of intravenous immunoglobulin is suggested in STSS in combination with antibiotics and surgery 6

Treatment Duration and Route

  • Treatment duration with penicillin should be 10 days to optimize cure in GABHS infections 4
  • A 5-day regimen is possible and approved by the United States Food and Drug Administration for cefpodoxime (a cephalosporin) and azithromycin (a macrolide) 4
  • Intravenous antibiotics may be superior to oral antibiotics for the treatment of beta-hemolytic streptococcal BSI, particularly in patients with severe infections 7

Related Questions

Is Macrobid (nitrofurantoin) effective for treating Beta-hemolytic Streptococcus infections?
What is the treatment for a urine culture showing 25,000 to 50,000 Colony Forming Units (CFU) of beta-hemolytic streptococcus?
What is the treatment for Beta-hemolytic Streptococcus (BHS) group G with amoxicillin (amoxicillin)?
Can beta-hemolytic Streptococcus (Strep) group C be treated with amoxicillin (Amoxicillin)?
What is the pediatric treatment for Group A beta-hemolytic streptococcal (GABHS) infection?
What are the vital areas in the body that, when struck, can cause fatal injury or death?
What is Epstein-Barr virus (EBV)?
What is the role of Amantadine (generic name) in breast cancer treatment?
What is the role of immunotherapy in breast cancer?
What antibiotic is used to treat a scrotal abscess?
What are the recommended antidepressants and anxiolytics (anti-anxiety medications) for a patient with the following genetic variants: ADRA2A mutation, COMT (Catechol-O-Methyltransferase) heterozygous, CYP1A2 (Cytochrome P450 1A2) *1A/*1A, CYP2B6 (Cytochrome P450 2B6) *4/*6, CYP2C19 (Cytochrome P450 2C19) *1/*1, CYP2C8 (Cytochrome P450 2C8) *1/*3, CYP2C9 (Cytochrome P450 2C9) *2/*3, CYP2D6 (Cytochrome P450 2D6) *4/*5, CYP3A4 (Cytochrome P450 3A4) *1/*1, CYP3A5 (Cytochrome P450 3A5) *1/*3, DBH (Dopamine Beta-Hydroxylase) heterozygous, DRD2 (Dopamine Receptor D2) wild-type, GRIK4 (Glutamate Receptor Ionotropic Kainate 4) mutation, HTR2A (5-Hydroxytryptamine Receptor 2A) -102 heterozygous and -1438 mutation, HTR2C (5-Hydroxytryptamine Receptor 2C) wild-type, MTHFR (Methylenetetrahydrofolate Reductase) -1298 wild-type and -677 heterozygous, and SLC6A4 (Solute Carrier Family 6 Member 4) S/LA, considering the patient's risk of hyperhomocysteinemia (elevated homocysteine levels) and vitamin B deficiency?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.